
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5722419/publications.pdf Version: 2024-02-01



THUO VAN EIMEREN

#	Article	IF	CITATIONS
1	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
2	Dysfunction of the Default Mode Network in Parkinson Disease. Archives of Neurology, 2009, 66, 877-83.	4.9	243
3	Stimulation of the subthalamic nucleus and impulsivity: Release your horses. Annals of Neurology, 2009, 66, 817-824.	2.8	225
4	Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease. Archives of Neurology, 2010, 67, 416-21.	4.9	220
5	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	2.2	179
6	Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial. Brain, 2013, 136, 2109-2119.	3.7	171
7	A systematic review on the applications of resting-state fMRI in Parkinson's disease: Does dopamine replacement therapy play a role?. Cortex, 2015, 73, 80-105.	1.1	161
8	Continuous theta burst stimulation of right dorsolateral prefrontal cortex induces changes in impulsivity level. Brain Stimulation, 2010, 3, 170-176.	0.7	150
9	Assessment of ¹⁸ F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408.	4.5	145
10	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. Neuropsychopharmacology, 2009, 34, 2758-2766.	2.8	140
11	Networks of tau distribution in Alzheimer's disease. Brain, 2018, 141, 568-581.	3.7	140
12	Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiology of Disease, 2010, 39, 98-104.	2.1	136
13	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
14	Hypothalamic Inflammation in Human Obesity Is Mediated by Environmental and Genetic Factors. Diabetes, 2017, 66, 2407-2415.	0.3	117
15	Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. Movement Disorders, 2011, 26, 225-233.	2.2	109
16	Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis. Cortex, 2017, 92, 119-138.	1.1	101
17	Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: A [¹⁵ 0] H ₂ 0 PET study. Human Brain Mapping, 2009, 30, 3901-3909.	1.9	99
18	In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 465-471.	1.2	93

#	Article	IF	CITATIONS
19	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
20	Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 934-939.	1.7	89
21	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	2.2	88
22	α-Synuclein in Parkinson's disease: causal or bystander?. Journal of Neural Transmission, 2019, 126, 815-840.	1.4	88
23	Brain Changes Associated with Postural Training in Patients with Cerebellar Degeneration: A Voxel-Based Morphometry Study. Journal of Neuroscience, 2013, 33, 4594-4604.	1.7	87
24	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. Neuropsychopharmacology, 2009, 34, 2758-66.	2.8	83
25	The effect of handedness on cortical motor activation during simple bilateral movements. NeuroImage, 2007, 34, 274-280.	2.1	81
26	Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction. Brain, 2020, 143, 944-959.	3.7	74
27	Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Structure and Function, 2011, 216, 289-299.	1.2	72
28	The Functional Anatomy of Impulse Control Disorders. Current Neurology and Neuroscience Reports, 2013, 13, 386.	2.0	64
29	Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach. Movement Disorders, 2009, 24, S703-10.	2.2	62
30	Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: A [11C]FLB 457 PET study. NeuroImage, 2009, 46, 516-521.	2.1	60
31	Implementation of visuospatial cues in response selection. NeuroImage, 2006, 29, 286-294.	2.1	56
32	Can Left-Handedness be Switched? Insights from an Early Switch of Handwriting. Journal of Neuroscience, 2007, 27, 7847-7853.	1.7	55
33	Tau pathology and cognitive reserve in Alzheimer's disease. Neurobiology of Aging, 2017, 57, 1-7.	1.5	50
34	Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. Brain, 2019, 142, 733-743.	3.7	50
35	Elevated in vivo [18F]â€AVâ€1451 uptake in a patient with progressive supranuclear palsy. Movement Disorders, 2017, 32, 170-171.	2.2	49
36	Alexithymia—an independent risk factor for impulsive ompulsive disorders in Parkinson's disease. Movement Disorders, 2014, 29, 214-220.	2.2	48

#	Article	IF	CITATIONS
37	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. Journal of Neurology, 2014, 261, 936-942.	1.8	46
38	The default mode network and cognition in Parkinson's disease: A multimodal restingâ€state network approach. Human Brain Mapping, 2021, 42, 2623-2641.	1.9	46
39	Cortical [<scp>¹⁸F</scp>] <scp>PI</scp> â€2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	2.2	46
40	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	3.3	36
41	An update on functional neuroimaging of parkinsonism and dystonia. Current Opinion in Neurology, 2006, 19, 412-419.	1.8	35
42	Tau-imaging in neurodegeneration. Methods, 2017, 130, 114-123.	1.9	34
43	Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease. Neurorehabilitation and Neural Repair, 2018, 32, 1055-1066.	1.4	33
44	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	3.3	33
45	Increased volume and impaired function: the role of the basal ganglia in writer's cramp. Brain and Behavior, 2015, 5, e00301.	1.0	30
46	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	1.2	30
47	Binding characteristics of [¹⁸ F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2957-2972.	2.4	30
48	Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression. American Journal of Geriatric Psychiatry, 2011, 19, 1016-1025.	0.6	27
49	The (in)consistency of changes in brain macrostructure in male paedophiles: A combined T1-weighted and diffusion tensor imaging study. Journal of Psychiatric Research, 2015, 68, 246-253.	1.5	23
50	Imaging Markers of Progression in Parkinson's Disease. Movement Disorders Clinical Practice, 2018, 5, 586-596.	0.8	23
51	Right lateralized motor cortex activation during volitional blinking. Annals of Neurology, 2001, 49, 813-816.	2.8	22
52	Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits. Journal of Nuclear Medicine, 2015, 56, 1916-1921.	2.8	22
53	Biomarkers of Parkinson's disease: 20Âyears later. Journal of Neural Transmission, 2019, 126, 803-813.	1.4	22
54	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3872-3885.	3.3	22

#	Article	IF	CITATIONS
55	ls Tau Imaging More Than Just Upside-Down ¹⁸ F-FDG Imaging?. Journal of Nuclear Medicine, 2017, 58, 1357-1359.	2.8	21
56	Connectomics and molecular imaging in neurodegeneration. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2819-2830.	3.3	21
57	Impulsivity is Associated with Increased Metabolism in the Fronto-Insular Network in Parkinson's Disease. Frontiers in Behavioral Neuroscience, 2015, 9, 317.	1.0	18
58	lmaging executive functions in Parkinson's disease: An activation likelihood estimation meta-analysis. Parkinsonism and Related Disorders, 2019, 63, 137-142.	1.1	18
59	One-Stop Shop: ¹⁸ F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. Journal of Nuclear Medicine, 2021, 62, 240-246.	2.8	18
60	Level of education mitigates the impact of tau pathology on neuronal function. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1787-1795.	3.3	16
61	Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease. Neurobiology of Aging, 2021, 106, 119-129.	1.5	15
62	Chemosensory processing in children with attention-deficit/hyperactivity disorder. Journal of Psychiatric Research, 2016, 76, 121-127.	1.5	14
63	Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2249-2256.	3.3	14
64	The Role of Tau Imaging in Parkinsonian Disorders. Current Neurology and Neuroscience Reports, 2018, 18, 86.	2.0	14
65	Effects of working memory training in patients with Parkinson's disease without cognitive impairment: A randomized controlled trial. Parkinsonism and Related Disorders, 2020, 72, 13-22.	1.1	14
66	Altered brain activation in a reversal learning task unmasks adaptive changes in cognitive control in writer's cramp. NeuroImage: Clinical, 2016, 10, 63-70.	1.4	13
67	Effects of Lee Silverman Voice Treatment BIG and conventional physiotherapy on non-motor and motor symptoms in Parkinson's disease: a randomized controlled study comparing three exercise models. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098674.	1.5	13
68	It's all about gains: Risk preferences in problem gambling Journal of Experimental Psychology: General, 2018, 147, 1241-1255.	1.5	13
69	Imaging movement-related activity in medicated Parkin-associated and sporadic Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 384-387.	1.1	12
70	Indication of retrograde tau spreading along Braak stages and functional connectivity pathways. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2272-2282.	3.3	12
71	Dopaminergic pathways and resting-state functional connectivity in Parkinson's disease with freezing of gait. NeuroImage: Clinical, 2021, 32, 102899.	1.4	12
72	Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy. Neurology, 2018, 90, 482-485.	1.5	10

#	Article	IF	CITATIONS
73	Assessment of Tau Tangles and Amyloid-Î ² Plaques Among Super Agers Using PET Imaging. JAMA Network Open, 2020, 3, e2028337.	2.8	10
74	Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 112.	2.5	10
75	Overlapping and distinct neural metabolic patterns related to impulsivity and hypomania in Parkinson's disease. Brain Imaging and Behavior, 2019, 13, 241-254.	1.1	8
76	Risk attitudes and digit ratio (2D:4D): Evidence from prospect theory. Journal of Risk and Uncertainty, 2020, 60, 29-51.	0.8	8
77	Effects of Home-Based Working Memory Training on Visuo-Spatial Working Memory in Parkinson's Disease: A Randomized Controlled Trial. Journal of Central Nervous System Disease, 2020, 12, 117957351989946.	0.7	8
78	Impaired self-awareness of cognitive deficits in Parkinson's disease relates to cingulate cortex dysfunction. Psychological Medicine, 2023, 53, 1244-1253.	2.7	7
79	Parameters from site classification to harmonize <scp>MRI</scp> clinical studies: Application to a multiâ€site Parkinson's disease dataset. Human Brain Mapping, 2022, 43, 3130-3142.	1.9	7
80	Longitudinal trimodal imaging of midbrain-associated network degeneration in Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	2.5	7
81	Probabilistic information on object weight shapes force dynamics in a grip-lift task. Experimental Brain Research, 2015, 233, 1711-1720.	0.7	6
82	Early-onset parkinsonism due to compound heterozygous POLG mutations. Parkinsonism and Related Disorders, 2016, 29, 135-137.	1.1	6
83	Assessing paedophilia based on the haemodynamic brain response to face images. World Journal of Biological Psychiatry, 2016, 17, 39-46.	1.3	6
84	Finding New Communities: A Principle of Neuronal Network Reorganization in Alzheimer's Disease. Brain Connectivity, 2021, 11, 225-238.	0.8	6
85	In search of convergent regional brain abnormality in cognitive emotion regulation: A transdiagnostic neuroimaging metaâ€analysis. Human Brain Mapping, 2022, 43, 1309-1325.	1.9	6
86	Working memory training increases neural efficiency in Parkinson's disease: a randomized controlled trial. Brain Communications, 2020, 2, fcaa115.	1.5	5
87	Entorhinal Tau Predicts Hippocampal Activation and Memory Deficits in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 1601-1614.	1.2	5
88	Motor trainingâ€related brain reorganization in patients with cerebellar degeneration. Human Brain Mapping, 2022, 43, 1611-1629.	1.9	4
89	Predicting Working Memory Training Responsiveness in Parkinson's Disease: Both "System Hardware― and Room for Improvement Are Needed. Neurorehabilitation and Neural Repair, 2021, 35, 117-130.	1.4	3
90	ICâ€Pâ€161: 18Fâ€PI2620 TAUâ€PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTIâ€CENTER EVALUATION.	Alzheime	r's

ICâ€Pâ€161: 18Fä€PI2620 IAUa and Dementia, 2019, 15, P128.

#	ARTICLE	IF	CITATIONS
91	Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme. Parkinsonism and Related Disorders, 2021, 93, 89-96.	1.1	3
92	Prefrontal D2â€receptor stimulation mediates flexible adaptation of economic preference hierarchies. Human Brain Mapping, 2013, 34, 226-232.	1.9	2
93	D26â€Pathological tau signal in huntington's disease – an in vivo [18F]-AV-1451 pet imaging report. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A44.1-A44.	0.9	2
94	Processing of probabilistic information in weight perception and motor prediction. Attention, Perception, and Psychophysics, 2017, 79, 404-414.	0.7	2
95	Discounting Behavior in Problem Gambling. Journal of Gambling Studies, 2021, , 1.	1.1	2
96	Inhibitory framing in hypersexual patients with Parkinson's disease. An fMRI pilot study. Experimental Brain Research, 2022, 240, 2097-2107.	0.7	2
97	Parkinsonian patients do not utilize probabilistic advance information in a grip-lift task. Parkinsonism and Related Disorders, 2019, 65, 67-72.	1.1	1
98	Assessment of Affective-Behavioral States in Parkinson's Disease Patients: Towards a New Screening Tool. Journal of Parkinson's Disease, 2021, 11, 1417-1430.	1.5	1
99	Oscillatory brain activity associated with skin conductance responses in the context of risk. Journal of Neurophysiology, 2021, 126, 924-933.	0.9	1
100	Never too little: Grip and lift forces following probabilistic weight cues in patients with writer's cramp. Clinical Neurophysiology, 2021, 132, 2937-2947.	0.7	1
101	[P2–200]: <i>IN VIVO</i> TAUOPATHY MEASURED WITH [18F]â€AVâ€1451 IS DIFFERENTIALLY RELATED TO C BIOMARKERS OF TAU IN ALZHEIMER'S DISEASE: THE INFLUENCE OF AMYLOID DEPOSITION. Alzheimer's and Dementia, 2017, 13, P683.	SF 0.4	0
102	[ICâ€₽â€183]: NETWORKS OF TAU DISTRIBUTION IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13 P136.	^{},} 0.4	0
103	[P1–006]: TAU PATHOLOGY BURDEN ASSOCIATED WITH LEVEL OF COGNITIVE RESERVE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P233.	0.4	0
104	[P1–467]: TAU PATHOLOGY BURDEN ASSOCIATED WITH LEVEL OF COGNITIVE RESERVE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P468.	0.4	0
105	[P1–468]: NETWORKS OF TAU DISTRIBUTION IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P468.	0.4	0
106	P1â€458: LEVEL OF BRAIN RESERVE ASSOCIATED WITH SPATIAL EXTENT OF TAUâ€NEURODEGENERATION PATTI IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P494.	ERN 0.4	0
107	From molecules to system failure: translational frontiers of multimodal imaging in neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2816-2818.	3.3	0
108	ICâ€₽â€003: THE CAPTAINS STUDY: STANDARDIZING VISUAL INTERPRETATION STRATEGIES FOR AMYLOID PET TRACERS. Alzheimer's and Dementia, 2019, 15, P14.	0.4	0

THILO VAN EIMEREN

#	Article	IF	CITATIONS
109	Resistance to tau and amyloid pathology supports superâ€aging. Alzheimer's and Dementia, 2020, 16, e036952.	0.4	Ο
110	Central autonomic dysfunction in multiple system atrophy: can we measure it with MRI?. Clinical Autonomic Research, 2020, 30, 185-187.	1.4	0
111	PET and SPECT Imaging of Neurodegenerative Diseases. , 2021, , 1309-1334.		Ο
112	The impact of subthalamic deep brain stimulation on belief revision and social validation. Parkinsonism and Related Disorders, 2021, 89, 84-86.	1.1	0
113	Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
114	The speed limits of tau spreading: The contribution of regional amyloid and education. Alzheimer's and Dementia, 2021, 17, .	0.4	0
115	Feasibility of short imaging protocols for [¹⁸ F]Plâ€2620 tauâ€PET in progressive supranuclear palsy. Alzheimer's and Dementia, 2021, 17, .	0.4	Ο
116	A gatekeeper for amyloid status based on FDGâ€₽ET and genetic risk in patients with mild cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.4	0